Neurocrine Biosciences (NASDAQ:NBIX) Given “Outperform” Rating at William Blair

William Blair reaffirmed their outperform rating on shares of Neurocrine Biosciences (NASDAQ:NBIX) in a research report report published on Monday morning,RTT News reports.

A number of other analysts also recently weighed in on NBIX. Needham & Company LLC restated a “hold” rating on shares of Neurocrine Biosciences in a report on Monday, November 11th. Raymond James reiterated an “outperform” rating and issued a $155.00 price target on shares of Neurocrine Biosciences in a research report on Thursday, October 10th. Barclays cut their price objective on Neurocrine Biosciences from $180.00 to $160.00 and set an “overweight” rating on the stock in a research note on Monday, September 9th. Wedbush reiterated an “outperform” rating and issued a $148.00 target price on shares of Neurocrine Biosciences in a report on Monday. Finally, Piper Sandler raised shares of Neurocrine Biosciences from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $131.00 to $159.00 in a research note on Thursday, August 29th. Five equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $165.00.

Neurocrine Biosciences Trading Up 5.0 %

Shares of NBIX stock opened at $133.05 on Monday. The firm has a market capitalization of $13.47 billion, a price-to-earnings ratio of 35.79 and a beta of 0.34. The business’s 50-day moving average price is $121.75 and its 200-day moving average price is $130.59. Neurocrine Biosciences has a 12 month low of $110.95 and a 12 month high of $157.98.

Insider Transactions at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Jude Onyia sold 2,331 shares of Neurocrine Biosciences stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $126.29, for a total transaction of $294,381.99. Following the completion of the transaction, the insider now owns 15,449 shares of the company’s stock, valued at $1,951,054.21. The trade was a 13.11 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 4.30% of the company’s stock.

Hedge Funds Weigh In On Neurocrine Biosciences

Large investors have recently modified their holdings of the company. State Street Corp lifted its stake in Neurocrine Biosciences by 11.7% in the 3rd quarter. State Street Corp now owns 5,148,293 shares of the company’s stock worth $593,186,000 after purchasing an additional 539,936 shares in the last quarter. 1832 Asset Management L.P. grew its position in Neurocrine Biosciences by 1,370.7% during the second quarter. 1832 Asset Management L.P. now owns 541,200 shares of the company’s stock worth $74,507,000 after buying an additional 504,400 shares in the last quarter. Los Angeles Capital Management LLC increased its stake in Neurocrine Biosciences by 639.6% in the 3rd quarter. Los Angeles Capital Management LLC now owns 420,748 shares of the company’s stock worth $48,479,000 after acquiring an additional 363,863 shares during the last quarter. AQR Capital Management LLC raised its holdings in shares of Neurocrine Biosciences by 23.0% in the 2nd quarter. AQR Capital Management LLC now owns 1,223,055 shares of the company’s stock valued at $166,959,000 after acquiring an additional 228,444 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its position in shares of Neurocrine Biosciences by 9.6% during the 2nd quarter. Renaissance Technologies LLC now owns 2,468,146 shares of the company’s stock valued at $339,790,000 after acquiring an additional 216,500 shares during the last quarter. 92.59% of the stock is currently owned by institutional investors.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.